Markets & Stocks
Rigorous individual licence process via the Swedish Medical Products Agency. Patient numbers slowly growing.
Medical cannabis (oils and flowers) is available in Sweden through a rigorous individual licence approval process. Specialists apply to the Swedish Medical Products Agency on behalf of patients. Initial licences are for 3 months with optional annual renewal. Patient numbers are slowly growing. The Karolinska Institute launched a national observational study in 2024 in collaboration with Curaleaf's Sapphire Clinics.
Medical cannabis in Sweden is available only through an individual licence approval process administered by the Swedish Medical Products Agency.
Specialist prescribers must submit an application providing evidence that the unregistered medical cannabis product is beneficial for the patient and that other treatment methods have been exhausted.
Initial licences are valid for 3 months, during which the patient's response to treatment is evaluated. If beneficial, the prescriber may apply for an annual licence.
In 2024, the Karolinska Institute, in collaboration with Curaleaf's Sapphire Clinics, launched a national observational study on cannabis-based preparations to build clinical evidence.
Who can prescribe: Specialist doctors must apply on behalf of their patient.
No official list of approved conditions. Access is based on individual medical need and evidence that other treatments have been exhausted.
Licences: Initial licence for 3 months (monitored), then annual renewal if treatment is beneficial.
Reimbursement: Variable — treatment reimbursement depends on the specific product and individual circumstances.
Patient numbers have been increasing in recent years.
Medical cannabis oils and flower products are available via individual licence.
Products must be unregistered (unlicensed) medicines — i.e. not already approved with marketing authorisations for those indications.
Supply is through licensed pharmaceutical importers and wholesalers.
Products are imported on a per-licence basis by licensed pharmaceutical wholesalers.
No significant domestic production industry exists in Sweden.
